

Vet Biotechnology Ltd (ACN 105 577 017)

NSX COMPANY ANNOUNCEMENT

NSX codes VBL, VBLO

June 27 2005 at 16:00 EST.

Australian Veterinarians Trained in Equine Stem Cell Services

Vet Biotechnology Ltd has trained the first group of Australian veterinarians in preparation for the upcoming launch of the Equine Stem Cell therapy for tendon and ligament injuries. A total of 78 equine veterinarians have been trained, including two from New Zealand, accounting for nearly 10% of equine veterinary surgeons in Australia.

This marks a significant milestone in the commercialisation of this technology in Australia, as veterinarians are required to complete the training course in order to register to use the services.

During April 2005 Vet Biotechnology Ltd invited Professor Roger Smith, Professor of Equine Orthopaedics at the Royal Veterinary College of London, to conduct training courses in the equine stem cell services. Professor Smith is one of the world's leading experts in the field of equine tendon and ligament injury and a co-inventor of the stem cell therapy.

Five training courses were held in Brisbane, Sydney, Melbourne, Adelaide and Perth. The participants consisted of equine veterinarians from top clinical practices and Universities around Australia. The five-hour training courses, including theory and practical components, provided veterinarians with a thorough knowledge of all aspects of the service to allow them to use the therapy once regulatory approval has been received in Australia.

The stem cell services are regulated by the Australian Pesticides and Veterinary Medicines Authority and require a permit before they can be marketed in Australia. Vet Biotechnology Ltd has recently completed the registration process and will offer the services in Australia shortly.

Vet Biotechnology Ltd will be holding additional training courses to ensure that all Australian equine veterinarians wanting the use the services are able to in the future.

Some of the most common orthopaedic injuries suffered by competition horses are to the suspensory ligament and bowed tendons. In many instances these injuries are career limiting and as such are a major cause of wastage in the industry.

The equine stem cell technology is a new approach to the management of equine tendon and ligament injuries. Over 250 veterinarians have now been trained in Europe and Australia and more than 100 horses treated since the services were made available in Europe.

Vet Biotechnology Ltd has an exclusive licence from VetCell BioScience Ltd (UK) to market this innovative therapy in Australia and New Zealand. The company's NSX listing was underwritten by Sydney based Martin Place Securities Pty Ltd.

For further information, contact:

Hugo Le Messurier
General Manager
Vet Biotechnology
Tel.: 08 8363 1159
Mobile: 0407 977 553

Vet Biotechnology Ltd

ACN 105 577 017
Suite 7, 114 Rundle Street
Kent Town South Australia 5067
Telephone: 61 8 8363 1159 Facsimile: 61 8 8362 2598
Web page: www.vetbiotechnology.com.au